Clinical Trials Logo

Clinical Trial Summary

Walnuts include many potentially beneficial micronutrients and phytochemicals, in this study we propose to examine the effects of walnuts independent of macronutrient content. The purpose of this proposal is to study in depth the short-term effects of walnut consumption in men and women with the metabolic syndrome.

Study Aim 1: To investigate the effects of walnuts (48gms per day over 3 days) on insulin resistance in subjects with the metabolic syndrome.

Study Aim 2: To investigate the effects of 48gms per day of walnuts over 3 days on lipids and inflammatory markers.

Study Aim 3: To assess the possible mechanisms of the biological effects of short-term walnut consumption through assessment of adipokines, resting metabolic rate, gene expression in white blood cells and the effect of walnuts when consumed as part of a mixed meal, on glucose excursions, insulin secretion and the excretion of gut peptides and free fatty acids.


Clinical Trial Description

During the whole study period, you will be asked to maintain a constant body weight and you will receive advice from the dietitian regarding a weight stable diet and exercise pattern. You will also be asked to avoid walnuts during the entire study period. The intervention and the measurements during each of the visits are described below.

If you agree to be in this study, you will be asked to read and sign this consent form. After you sign the consent form, the following things will happen:

1. Screening Procedures: Screening procedures are tests and procedures that will be done to determine if you are eligible to take part in the research study. For this research study, the screening procedures include:

1. A detailed medical history and interview about lifestyle factors and medication use

2. A brief physical examination to document any abnormalities in your body appearance and measurement of weight, height and waist circumference.

3. Drawing of blood from the forearm for fasting blood glucose (blood sugar), lipid profile (cholesterol and other fats in blood), creatinine (a measure of your kidney function), and complete blood count (CBC).

4. Collection of urine for a HCG pregnancy test (women only)

For the blood tests, you will be asked not to eat or drink anything (except water) from 8 pm the previous evening until you arrive for the study visit the following morning.

Samples of your blood will be stored under code to be used for future research by the BIDMC investigators but your name will not be identified. If for any reason you have decided to withdraw from the study or if you have not met the criteria for enrollment into the study, all the blood drawn at the screening visit will be discarded.

Next, you will meet with a research dietician to receive instructions for the 2-week run-in period (see below).

2. Randomization Procedures:

You will be randomly assigned (like the flip of a coin) to receive either walnut containing milkshake or placebo containing milkshake on your first visit. Each participant will receive walnut containing milkshake during one visit and a milkshake that looks and tastes the same but without walnuts (placebo) on the other visit but the order of the visits will be randomized.

3. Research Procedures: If you qualify to take part in this research study, you will undergo these research procedures:

Run-in period:

You will meet with a research dietician who will provide instructions about maintaining your normal diet and physical activity pattern and about avoiding walnut-containing foods and drinks.

Study Visit 1 and 2 Each study visit involves a 4-day (4 overnight) stay at the General Clinical Research Center. You will be admitted at 9pm the evening before the first day of the visit. You will be asked to complete a hunger questionnaire each morning before you have had anything to eat. You will receive a milkshake each morning containing either with or without walnuts. We will repeat the hunger questionnaire before your lunch each day. You will be provided with lunch and dinner based on what you like to eat. The calorie content of the lunch and dinner will be controlled so that you will neither gain or lose weight during your stay.

Day 1 The following morning the following tests will be performed; Measure your weight, waist circumference, and blood pressure. Resting Metabolic Rate Fasting blood tests Body composition Mixed meal challenge You will receive your first milkshake as part of the mixed meal challenge.

Day 2 On day 2 there is no testing but you will complete the hunger questionnaire and receive another milkshake for breakfast.

Day 3

On day 3 you will have the following tests performed:

Insulin Suppression Test Fasting blood sample At the end of the insulin suppression test, you will receive another milkshake.

Day 4 On the morning of your last day you will have repeat testing as on the first day of the visit and will leave the hospital at mid-day after the testing is complete.

Washout phase Between the 2 study visits you will enter a washout phase where you will continue your normal healthy diet and exercise but avoid walnuts in your diet. After 1 month of washout you will return to the GCRC for your second study visit.

4. Tests performed during the study

Resting Metabolic Rate RMR is the amount of calories you burn without doing any physical work. Your RMR will be measured with a commonly used instrument. You will be asked to lie quietly in bed and stay awake with a large plastic hood over your head and upper body for about 20 minutes and breathe normally while the air you breathe out is being collected.

Fasting blood tests Blood samples will be used to measure sugar, insulin levels, lipids (LDL, HDL, and total cholesterol, triglycerides), hormones (such as leptin, resistin and adiponectin) and blood markers of inflammation (such as TNF and CRP). We will also perform a blood test to measure the expression of genes involved in metabolism in your white blood cells. For the blood tests, you will be asked not to eat or drink anything (except water) from 8 pm the previous evening until. In addition, you will be asked not to participate in vigorous physical activity on the day before the visit. Samples of your blood will be stored under code to be used for future related blood measurements by the BIDMC investigators but your name will not be identified.

Body composition To measure the amount of fat in your body we will use bioelectrical impedance analysis. During this procedure you will lie down and the speed of an electric signal through your body will be measured. This signal is not painful.

Mixed meal challenge You will have a small catheter (a small plastic tube) placed in a vein with a needle in your forearm to draw blood. This will prevent the need for multiple needle sticks for the required blood draws. The catheter will be taped to stay in place for approximately three hours. You will drink a milkshake and your blood will be drawn through the catheter 15 min after the milkshake is given and then at 30-minute intervals for 3 hours to measure how you metabolize the nutrient drink.

Insulin Suppression Test (also called Galvin's Index) This test consists of an overnight fast (nothing to eat or drink after 11pm the night before), after which two IV lines will be placed in your arms. Glucose, insulin,octreotide (a hormone commonly used in clinical practice for treating several different diseases) and albumin ( a protein found in blood) will be infused through the IV. Blood samples will be drawn through the other IV line at times -10 minutes, 0 minutes, and every 30 minutes for two and a half hours, then every 10 minutes for an additional 30 minutes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00525629
Study type Interventional
Source Beth Israel Deaconess Medical Center
Contact
Status Completed
Phase N/A
Start date February 2007
Completion date December 2008

See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A